Breaking Finance News

Illumina, Inc. (NASDAQ:ILMN) stock price target increased to $138.44, issued a research note today by Vetr Inc.

Yesterday Illumina, Inc. (NASDAQ:ILMN) traded -4.07% lower at $127.72. The company’s 50-day moving average is $139.08 and its 200-day moving average is $152.96. The last closing price is down -16.50% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 0 shares of the stock traded hands, down from an average trading volume of 1,352,870

In a report released on 12/1/2016 Vetr Inc. increased the stock price target of Illumina, Inc. (NASDAQ:ILMN) to $138.44 indicating a possible upside of 0.08%.

Previously on 2/04/2016, Canaccord Genuity reported on Illumina, Inc. (NASDAQ:ILMN) increased the target price from $0.00 to $160.00. At the time, this indicated a possible upside of 0.07%.

See Chart Below

Illumina, Inc. (NASDAQ:ILMN)

Illumina, Inc. has a 52 week low of $127.10 and a 52 week high of $196.47 with a P/E ratio of 42.86 The company’s market cap is currently $0.

In addition to Vetr Inc. reporting its stock price target, a total of 19 brokers have issued a research note on the company. The average stock price target is $154.53 with 4 brokers rating the stock a strong buy, 4 brokers rating the stock a buy, 15 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Illumina, Inc. (NASDAQ:ILMN)

Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.